'Recipe to be dead-last': MEPs push to make biotech’s SPC reward count
MEPs backing the EU Biotech Act argue that an additional year of supplementary protection for a narrowly defined group of biotech medicines could encourage European research, manufacturing and patient access. Eligibility would require a new active substance, distinct and sufficiently safe and effective treatment, clinical trials in more than two EU member states, and at least one manufacturing step in the Union. Stine Bosse proposes early SPC candidate status linked to the European Medicines Agency’s PRIME scheme, a longer extension for orphan drugs and industry contributions to public-health infrastructure; Wouter Beke warns that overly strict conditions could undermine the incentive. Public payers and health technology assessment bodies warn of higher costs, while industry-backed modelling describes the budget impact as negligible. Committee votes are expected in December and a plenary vote around the turn of the year; trilogue negotiations are unlikely before 2027.
Style rédactionnelInformatif
Mostly factual reporting, with attributed advocacy and competing arguments from MEPs and industry and public-payer stakeholders.